A 28-Day, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Anti-Inflammatory Effect and Steady-State Pharmacokinetics of SB-681323 (7.5 mg) in Subjects With Coronary Heart Disease (CHD) Undergoing Elective Percutaneous Coronary Interventions (PCI).

Trial Profile

A 28-Day, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Anti-Inflammatory Effect and Steady-State Pharmacokinetics of SB-681323 (7.5 mg) in Subjects With Coronary Heart Disease (CHD) Undergoing Elective Percutaneous Coronary Interventions (PCI).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2012

At a glance

  • Drugs Dilmapimod (Primary)
  • Indications Atherosclerosis; Coronary artery disease
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Oct 2008 Actual start date changed from Feb 2006 to Mar 2006 as reported by ClinicalTrials.gov.
    • 14 Oct 2008 Status changed to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top